COLEC12 <sup>high</sup> TAMs Orchestrate Lenvatinib Resistance and Cancer Stemness in HCC via Paracrine NRG1-HER2/HER3 Signaling
Our work establishes the COLEC12high TAM / NRG1 axis as a master regulator of therapeutic resistance and identifies NRG1 as a predictive biomarker, providing a clinically actionable strategy to overcome lenvatinib resistance in HCC.
Authors
- Yan Zeng (ORCID: https://orcid.org/0000-0002-9823-1266)
- Shanshan Huang (ORCID: https://orcid.org/0009-0001-8058-6077)
- Z. Huang (ORCID: https://orcid.org/0000-0002-7195-3189)
- Jianxing Zhang (ORCID: https://orcid.org/0000-0003-4091-2189)
- L. Qiao
- Chenwei Wang (ORCID: https://orcid.org/0000-0002-2097-8634)
- Yi Niu (ORCID: https://orcid.org/0000-0003-4286-941X)
- Zongfeng Wu
- Wei He
- Yu Li
- Binkui Li
- Shaoru Liu
- Dinglan Zuo
- Yichuan Yuan
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- Clinical and Molecular Hepatology
- Published
- 2026-01-20
- DOI
- https://doi.org/10.3350/cmh.2025.1059
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Sun Yat-sen University
- Sun Yat-sen University Cancer Center